Abstract
Background We evaluated mRNA COVID-19 vaccine effectiveness (VE) for the XBB.1.5 formulation against COVID-19 hospitalizations among adults aged ≥60 years during a ten-month follow-up period.
Methods We conducted a test-negative case-control study using Quebec population-based administrative data. Specimens collected from individuals aged ≥60 years tested at an acute-care hospital from October 2023 to August 2024 were considered test-positive cases if hospitalized for COVID-19, or controls if test-negative for SARS-CoV-2. Vaccination was defined by receipt of at least one mRNA XBB-vaccine (autumn or spring) dose. Multivariate logistic regression analyses estimated VE relative to several comparator groups, primarily those last-vaccinated in 2022, by subvariant predominant period (XBB, JN and KP), by time since XBB-vaccination and by number of XBB-vaccine doses (KP period).
Results Participants overall and by XBB, JN and KP periods included: 5532 (4.9%) test-positive cases (1321, 1838 and 1372, respectively) and 108473 (95.1%) test-negative controls (12881, 53414 and 28595, respectively); 14584 specimens were collected during periods of subvariant cocirculation. By subvariant period, 3322 (25.8%), 27041 (50.6%) and 15401 (53.9%) controls, respectively, were considered XBB-vaccinated. Overall VE was 30% (95%CI:24–35) and by XBB, JN or KP period: 54% (95%CI:46–62), 23% (95%CI:13–32) and 0% (95%CI:-18–15), respectively. During each subvariant period, the hospitalization risk was reduced only during the first four months post-vaccination.
Conclusions Among individuals aged ≥60 years, mRNA XBB-vaccination provided meaningful, albeit limited and short-term, protection against COVID-19 hospitalization due to XBB, JN and KP subvariants in. Better vaccines are needed to effectively reduce COVID-19 disease burden.
summary Based on a population-based test-negative study, XBB.1.5-vaccine effectiveness against COVID-19 hospitalizations was 30% from October 2023 to August 2024 among ≥60-year-olds. By subvariant period, effectiveness was 54% (XBB-period), 23% (JN-period) and 0% (KP-period), with no protection past 5-6 months post-XBB-vaccination.
Competing Interest Statement
SC, IGI and JP report funding from the Ministère de la santé et des services sociaux du Québec to conduct this work, paid to their institution. DMS reports funding from Public Health Agency of Canada and British Columbia Center for Diseases Control Foundation for Public Health for influenza and COVID-19 studies but not pertaining to the current study; from Michael Smith Foundation for Health Research and from Canadian Institutes of Health Research for COVID-19 studies but not pertaining to the current study; all grants were paid to her institution. All other authors report no potential conflicts.
Funding Statement
This work was funded by the Ministère de la santé et des services sociaux du Québec
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Centre de Recherche du Centre Hospitalier Universitaire du Québec-Université Laval gave approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos